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Abstract  
Background 
Few studies describe both inpatient and outpatient treatment and outcomes of patients with acute venous 
thromboembolism in the US.  
Methods 
A multi-institutional cohort of patients diagnosed with confirmed pulmonary embolism  and/or deep 
venous thrombosis during years 2004 through 2010 was established from four large, US-based 
integrated healthcare delivery systems. Computerized databases were accessed and medical records 
reviewed to collect information on patient demographics, clinical risk factors, initial antithrombotic 
treatment, and vital status. Multivariable Cox regression models were used to estimate the risk of death 
at 90 days.   
Results 
The cohort comprised 5,497 adults with acute venous thromboembolism. Pulmonary embolism was 
predominantly managed in the hospital setting (95.0%) while 54.5% of patients with lower extremity 
thrombosis were treated as outpatients. Anticoagulant treatment differed according to thromboembolism 
type: 2,715 (93.7%) of patients with pulmonary embolism and 1,634 (87.4%) of patients with lower 
extremity thrombosis were discharged on anticoagulants, compared to 288 (80.7%) patients with upper 
extremity thrombosis and 70 (55.6%) patients with other thrombosis. While 4.5% of patients died during 
the index episode, 15.4% died within 90 days. Pulmonary embolism was associated with a higher 90-day 
death risk than lower extremity thrombosis (adjusted hazard ratio [aHR] 1.23 [1.04-1.47]) as was not 
being discharged on anticoagulants (aHR 5.56 [4.76-6.67]).  
Conclusions 
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In this multicenter, community-based study of patients with acute venous thromboembolism, 
anticoagulant treatment and outcomes varied by thromboembolism type. Although case-fatality during 
the acute episode was relatively low, 15.4% of people with thromboembolism died within 90 days of the 
index diagnosis.  
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Introduction 
Venous thromboembolism, primarily pulmonary embolism and deep venous thrombosis, affects 
an estimated 750,000 people in the United States (US) each year and causes more than 100,000 deaths 
annually.
1-3
 Yet there are relatively few large US-based studies that describe in detail the characteristics, 
treatment, and outcomes of venous thromboembolism. Many studies rely solely on diagnosis codes to 
identify thromboembolism, which may not accurately identify true thrombotic events
4-8
. Administrative 
databases also lack complete data on patient risk factors, acuity of illness, and treatment plan.
9
 Most 
studies focus on hospitalized patients,
4-7, 10
 despite acute management moving towards outpatient 
settings
11
, or only include patients discharged on anticoagulants.  
To more completely describe the treatment and outcomes of patients with venous 
thromboembolism, we conducted a multicenter observational cohort study of patients with acute 
thrombosis within the Cardiovascular Research Network Venous Thromboembolism (CVRN VTE) 
consortium. Our goal was to describe treatment strategies, morbidity, and mortality outcomes of both 
inpatients and outpatients with acute thromboembolism.  
 
Materials and Methods 
Cohort Assembly 
The CVRN VTE study is a retrospective cohort of patients with venous thromboembolism 
enrolled in one of four integrated healthcare delivery systems in the US. The four systems represented 
diverse geographic patient sources, with service provided during the study period to the following 
populations: Kaiser Permanente Northern California (>3.2 million members in Northern California 
during the study period), Kaiser Permanente Colorado (>460,000 members in the Denver, Colorado 
metropolitan area), Geisinger Health System, now Geisinger (~2.5 million members in central and 
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northwest Pennsylvania), and Marshfield Clinic (>550,000 members in central and northwest 
Wisconsin). All clinical sites used electronic health record systems during the time period of the study. 
The study was approved by the institutional review board at each of the participating sites according to 
local policies and procedures. A waiver of informed consent was obtained due to the nature of the study. 
The cohort was assembled by first searching computerized health plan databases for all 
individuals ≥21 years of age with a clinical encounter (inpatient, emergency department [ED] or 
ambulatory) associated with either a primary or secondary International Classification of Diseases, 
Ninth Revision (ICD-9) diagnosis code of venous thromboembolism, between October 1, 2004 and 
December 31, 2010. Only the first encounter with a code for venous thromboembolism during the time 
period was reviewed. Because the focus of the study was on incident thrombosis, patients with a prior 
code for thrombosis while enrolled in the health plan, or prescribed anticoagulants within 4 years prior, 
were excluded. We included only subjects with continuous health plan and pharmacy benefits for at least 
12 months prior to the index thrombotic encounter.  
Events were categorized as pulmonary embolism (ICD-9 code 415.1x), lower extremity deep 
venous thrombosis (451.1x, 451.2, 451.81, 453.4x, 453.5x), upper extremity deep venous thrombosis 
(451.83, 451.84, 451.89, 453.72, 453.73, 453.74, 453.75, 453.76, 453.77, 453.82, 453.83, 453.84, 
453.85, 453.86, 453.87), and other venous thrombosis (451, 451.9, 452, 453, 453.0, 453.1, 453.2, 453.3, 
453.79, 453.8, 453.89, 453.9). We did not include pregnancy-related thromboembolism or superficial 
thrombophlebitis as part of this study.  
 
Validation of Venous Thromboembolic Events 
We identified 42,941 unique individuals with an incident clinical encounter assigned a diagnosis 
of thromboembolism meeting inclusion criteria. To attain a target sample size of ~5500 patients with 
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valid, acute venous thrombosis, we initially selected 7,334 clinical encounters for review, comprising all 
available patients in two of the health systems and a random sample of patients from the other two 
systems. All available inpatient admission, transfer, discharge, ED, and outpatient encounter notes were 
redacted, as well as relevant radiology reports within 72 hours before and after the index venous 
thromboembolism date. Trained physician and pharmacist reviewers then reviewed medical records 
using a structured adjudication tool to determine whether the encounter represented a valid acute 
thromboembolism. Events were considered valid if there was radiographic, operative, or autopsy 
evidence of an acute thrombosis, or if a physician documented in the medical record that an acute 
venous thromboembolism had occurred during that episode of care. An encounter with a prior history of 
venous thromboembolism whose acute management was not contiguous with the current episode was 
not considered an acute event. Superficial venous thromboses/thrombophlebitis were not considered 
valid events.  
Of the initial 7,334 patients, 7,063 had medical records available for review. However, only 
2,135 (30.2%) were determined upon review to represent valid thromboembolism events, with 
ambulatory encounters and those with thrombosis codes in the secondary position less likely to represent 
true acute events (results of the validation process described previously).
8
 To enhance the likelihood of 
finding valid encounters, we then randomly selected an additional set of patients for review, restricting 
to hospital/ED encounters with a primary diagnosis of thrombosis in years 2006 or later, until we 
reached a total of ~5500 valid events (Supplemental Figure).   
 
Presentation, Treatment, and Outcomes of Acute Venous Thromboembolism 
Clinical and demographic information were obtained from computerized health plan databases. 
Relevant medical conditions within 4 years prior to the index event were identified using inpatient or 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
outpatient ICD-9 codes. Ascertainment of diabetes mellitus and malignant cancer was supplemented 
using regional diabetes and cancer registries from some of the health systems.
12, 13
 ICD-9 codes were 
used to calculate a Charlson comorbidity index score for each patient.
14
 Receipt of medications to 
manage chronic cardiovascular diseases were identified by searching health plan pharmacy dispensing 
databases within 30 days prior to the index thromboembolism date.  
Clinician reviewers collected information on thromboembolism type, smoking history, and 
documented immobility or injury (such as surgery within 30 days, trauma or prolonged immobility 
within 7 days, indwelling venous catheters). Thromboembolic events were defined as “unprovoked” if 
they occurred in the absence of identifiable risk factors such as diagnosed cancer or documented history 
of recent surgery, immobility, or injury. 
Reviewers assessed whether antithrombotic medications were prescribed at the end of the 
encounter and categorized as oral anticoagulants (specifically warfarin, as direct oral anticoagulants 
were not yet approved for use in thromboembolism), parenteral anticoagulants (e.g., low-molecular-
weight heparins, fondaparinux), and antiplatelet agents (aspirin, clopidogrel, ticlopidine, dipyridimole, 
and cilostazol). For encounters without antithrombotic treatment at discharge, the encounter 
documentation was reviewed for potential reasons why treatment was not issued. 
The primary outcome for the study was death from any cause within 90 days after the index 
thromboembolic event. Secondary outcomes included death during the index event, death within 30 
days, and new functional impairment at discharge. Death was determined from medical record review, 
health plan databases, and the Social Security Index death files. Functional impairment was ascertained 
by review of the encounter documentation. Reviewers used their clinical judgement to determine 
whether the patient suffered functional consequences as a result of the thrombotic event and categorized 
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as “at least some functional impairments related to the event”, “no functional impairments related to the 
event”, or “unknown”.  
 
Statistical Analysis 
 The study objective was to compare anticoagulant treatment patterns and short-term outcomes by 
thromboembolism type (any pulmonary embolism, lower extremity thrombosis, upper extremity 
thrombosis, and other venous thromboses). We first used descriptive statistics to report clinical 
characteristics, treatment, and outcomes by event type, using ANOVA for continuous variables and 
2
 
tests for categorical variables when comparing amongst thromboembolism types. We then modeled 
death within 90 days as a function of event type and anticoagulant treatment, developing a multivariable 
Cox regression model that incorporated variables that have been or could be plausibly be related to 
short-term mortality, including risk factors for thrombosis, coexisting medical conditions, Charlson 
comorbidity risk score, and baseline use of medications to manage cardiovascular conditions. A two-
sided p-value less than 0.05 was considered statistically significant. All analyses were performed using 
SAS version 9.1 (SAS Institute, Inc., Cary, NC).  
 
 
 Results 
The cohort comprised 5,497 adults with confirmed acute incident venous thromboembolism. The 
mean age of the cohort was 65.7 years and 51.4% were women (Table 1). The majority of subjects 
(n=3,056) had pulmonary embolism with or without concomitant deep venous thrombosis, followed by 
patients with isolated lower extremity thrombosis (n=1,928). Relatively few patients had isolated upper 
extremity thrombosis (n=383) or other forms of thrombosis (n=130).  
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Cancer was a common comorbid condition, present in 2,022 (36.4%) of patients overall and with 
a particularly high prevalence among people with upper extremity thrombosis (44.9%). Recent 
immobility and/or injury was identified in 2,302 (41.9%) of the cohort. In 188 (49.1%) of the 383 
patients with upper extremity thrombosis, an indwelling venous catheter was identified as a potential 
provoking event. For 1,254 (22.8%) of patients, the event was categorized as unprovoked (e.g., no 
history of immobility, injury, recent hospitalization, or known cancer).  
 
Treatment and outcomes of acute venous thromboembolism 
The majority of patients received anticoagulants (oral and/or parenteral) at discharge, although 
treatment differed by thrombosis type (Table 2). Among survivors of the acute event, 92.8% of those 
with pulmonary embolism and 86.9% of those with lower extremity thrombosis were discharged on 
anticoagulants. Anticoagulant treatment was less common among patients with thromboses in other 
locations: 80.1% of patients with upper extremity thrombosis and 54.8% of patients with other 
thrombosis. Few patients (2.9%) were discharged on antiplatelet agents only. Among the 430 patients 
who survived the acute episode and were not prescribed antithrombotic therapy at discharge, bleeding 
risk and/or poor prognosis were identified by reviewers as a rationale to avoid anticoagulants in 75.3% 
and 61.2% of patients, respectively. 
Death during the index thrombotic episode occurred in 5.2% of patients with pulmonary 
embolism and 3.1% of patients with lower extremity thrombosis (Table 2). Among patients who 
survived the index event, reviewers noted “at least some functional impairments related to the event” 
more commonly among patients with pulmonary embolism (26.1%) than patients with isolated lower 
extremity thrombosis (15.6%. p<0.01). The proportion of patients who died after the index event 
continued to rise after discharge: all-cause mortality was 8.0% at 30 days and 15.4% at 90 days (Table 
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2). Among all inpatients, 9.8% died within 30 days and 17.9% died within 90 days. In contrast, 2.5% 
and 7.7% of ED/ambulatory patients died within 30 and 90 days, respectively. Crude mortality at 90 
days was highest in patients with other thrombosis (25.4%), followed by isolated upper extremity 
thrombosis (20.9%) and then pulmonary embolism (15.5%). However, after multivariable adjustment, 
no significant differences in 90-day death rates persisted between these three groups (Table 3). In a 
multivariable Cox regression model, patients with pulmonary emboli had a higher 90-day mortality risk 
compared to patients with lower extremity thrombosis, with an adjusted hazard ratio [aHR] of 1.2 (95% 
confidence interval [CI] 1.04-1.5). Not being discharged on anticoagulants was associated with 
significantly higher mortality risk, aHR 5.6 (95% CI: 4.8-6.7). Other clinical factors associated with a 
higher risk of death at 90 days included older age, current smoking, a diagnosis of cancer, and higher 
Charlson comorbidity scores (Table 3).  
 
Discussion 
 Our study provides a unique examination of the acute presentation, treatment, and outcomes of 
inpatients and outpatients with venous thromboembolism across four geographically diverse US-based 
health systems. Although most patients with thromboembolism were treated with anticoagulants, 1 in 10 
people were not, frequently due to concerns for bleeding risk or poor clinical prognosis. The short-term 
outcomes after a diagnosis of thromboembolism are consequential, with 15.4% of patients dying within 
90 days after initial diagnosis.  
Strengths of our study include its diverse source population, inclusion of events from both 
inpatient and outpatient settings, and validation of index thromboembolic events and collection of data 
through review of medical records. These methods were then facilitated with additional data from 
comprehensive electronic medical records at each study site. We were able to identify health care 
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utilization even if patients presented to facilities outside of the healthcare system, as all patients were 
enrolled in integrated healthcare delivery systems. In contrast, most large, contemporary studies 
addressing acute venous thromboembolism in the US have relied on administrative data obtained from 
hospital settings, providing an incomplete perspective.
4, 5, 15, 16
 Our prior work found that only 30.9% of 
ambulatory encounters with a thrombosis diagnosis actually represented an acute thrombotic event .
8
 
With the advent of direct oral anticoagulants, it is likely that the outpatient treatment of 
thromboembolism will become even more prevalent. 
Descriptions of short-term outcomes following acute pulmonary embolism vary across different 
studies. The Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry 
(EMPEROR) study reported a relatively low 30-day mortality rate (5.4%) in patients with pulmonary 
embolism presenting to US-based emergency departments between 2005-2008
17
, comparable to the 
international Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) registry (5.9% 
mortality).
18
 In contrast, a Canadian study found a substantially higher (16.9%) 30-day mortality rate 
among hospitalized and ambulatory patients
19
 as did a Danish nationwide registry (19.9% 30-day 
mortality after hospitalization).
20
 The Nationwide Inpatient Sample, a nationally representative sample 
of US-hospital admissions, reported a declining risk of inpatient death after pulmonary embolism (7.1% 
in 1993 and 3.2% in 2012).
21
 Our study found that 5.2% of patients with pulmonary embolism died 
during the index event and 8.7% at 30 days. 
Variation in short-term outcomes observed across studies may have several possible 
explanations. One possibility may be differences in anticoagulation management and delivery; for 
example, the four health systems in our study were all integrated healthcare delivery models of care. Our 
study included patients treated in outpatient settings, who may have less severe disease and better 
functional status. Previous studies have shown that selective outpatient treatment of acute pulmonary 
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embolism is feasible and effective.
22-25
 Despite this, outpatient management of pulmonary embolism is 
still limited in clinical practice
18, 26-28
 Different follow-up periods could account for differences in case-
fatality rates, given secular trends of lower mortality from pulmonary embolism within the last two 
decades.
4, 18, 21
 Finally, the introduction and increased use of multidetector computed tomography may 
have contributed to including less severe or even clinically unimportant pulmonary emboli.
7, 29
   
In contrast to pulmonary embolism, we observed less discrepancy in 30-day mortality after deep 
venous thrombosis in our cohort compared to findings from the Worcester VTE study (5.4%),
30
 a 
Canadian study (7%),
19
 and a Danish registry (4.5%).
20
 Our results are consistent with other studies that 
show pulmonary embolism as an independent predictor of short-term death compared to deep venous 
thrombosis alone.
30-32
 
Most patients in our study were prescribed anticoagulants and anticoagulant treatment was 
associated with a significantly lower risk for 90-day death. Causality between treatment and mortality 
cannot be inferred, as it is highly likely there was channeling bias, where patients with limited life 
expectancy or at higher risk for adverse outcomes from anticoagulants were less likely to be prescribed 
treatment. Indeed, poor prognosis was commonly cited as a reason for avoiding therapy. Anticoagulation 
treatment varied by event type, with upper extremity thrombosis and thrombosis in unusual sites less 
likely to be treated with anticoagulants.  
Our results have several implications for practitioners, policy makers, and researchers. Our 
results underline the persistent public health importance of venous thromboembolism and highlight the 
substantial short-term mortality after incident thrombosis. Efforts to prevent thromboembolism and 
ensure timely diagnosis and treatment should be undertaken. Given that more than 19 billion dollars 
annually are spent for the treatment of thromboembolism in the US,
33
 with a substantial amount 
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accounting from in-hospital care,
34
 better education of clinicians about the appropriate risk stratification 
and the possibility of home treatment of patients could help to reduce costs.
26
  
There are also several limitations to this study. We oversampled for hospitalized patients, so 
preferentially captured more pulmonary embolism events and our findings might have been slightly 
biased towards patients with more severe disease. As a retrospective and observational study of clinical 
care, variation in documentation could have contributed to misclassification of certain variables, such as 
prior injury or immobility. Our study specifically addressed incident thrombosis and did not include 
recurrent thromboembolic events, which have different risk factors and outcomes. Finally, our study did 
not include the experience of patients with thrombosis who were treated with the direct oral 
anticoagulants, which were not yet in widespread use during the study period.
35
 Nevertheless, VKAs 
remain commonly prescribed in the US and worldwide.
36, 37
 
 
Conclusions 
 This large, multicenter cohort of patients with acute venous thromboembolism provides unique 
insights into treatment and outcomes of thromboembolism and demonstrated that anticoagulant 
treatment patterns and short-term mortality varied by event-type. Although case-fatality during the acute 
episode was relatively low, 15.4% of affected patients with acute thromboembolism died within 90 days 
of the incident event, highlighting the need for effective strategies to improve outcomes in this 
population. As treatment options continue to expand beyond warfarin to include direct oral 
anticoagulants, it is important to document how treatment and outcomes of thromboembolism evolves 
over time. 
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Supplementary Figure. Flow diagram of how 5,497 patients with valid, incident venous 
thromboembolism were identified for the CVRN VTE cohort 
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Abstract  
Background 
Few studies describe both inpatient and outpatient treatment and outcomes of patients with acute venous 
thromboembolism in the US.  
Methods 
A multi-institutional cohort of patients diagnosed with confirmed pulmonary embolism  and/or deep 
venous thrombosis during years 2004 through 2010 was established from four large, US-based 
integrated healthcare delivery systems. Computerized databases were accessed and medical records 
reviewed to collect information on patient demographics, clinical risk factors, initial antithrombotic 
treatment, and vital status. Multivariable Cox regression models were used to estimate the risk of death 
at 90 days.   
Results 
The cohort comprised 5,497 adults with acute venous thromboembolism. Pulmonary embolism was 
predominantly managed in the hospital setting (95.0%) while 54.5% of patients with lower extremity 
thrombosis were treated as outpatients. Anticoagulant treatment differed according to thromboembolism 
type: 2,715 (93.7%) of patients with pulmonary embolism and 1,634 (87.4%) of patients with lower 
extremity thrombosis were discharged on anticoagulants, compared to 288 (80.7%) patients with upper 
extremity thrombosis and 70 (55.6%) patients with other thrombosis. While 4.5% of patients died during 
the index episode, 15.4% died within 90 days. Pulmonary embolism was associated with a higher 90-day 
death risk than lower extremity thrombosis (adjusted hazard ratio [aHR] 1.23 [1.04-1.47]) as was not 
being discharged on anticoagulants (aHR 5.56 [4.76-6.67]).  
Conclusions 
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In this multicenter, community-based study of patients with acute venous thromboembolism, 
anticoagulant treatment and outcomes varied by thromboembolism type. Although case-fatality during 
the acute episode was relatively low, 15.4% of people with thromboembolism died within 90 days of the 
index diagnosis.  
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Introduction 
Venous thromboembolism, primarily pulmonary embolism and deep venous thrombosis, affects 
an estimated 750,000 people in the United States (US) each year and causes more than 100,000 deaths 
annually.
1-3
 Yet there are relatively few large US-based studies that describe in detail the characteristics, 
treatment, and outcomes of venous thromboembolism. Many studies rely solely on diagnosis codes to 
identify thromboembolism, which may not accurately identify true thrombotic events
4-8
. Administrative 
databases also lack complete data on patient risk factors, acuity of illness, and treatment plan.
9
 Most 
studies focus on hospitalized patients,
4-7, 10
 despite acute management moving towards outpatient 
settings
11
, or only include patients discharged on anticoagulants.  
To more completely describe the treatment and outcomes of patients with venous 
thromboembolism, we conducted a multicenter observational cohort study of patients with acute 
thrombosis within the Cardiovascular Research Network Venous Thromboembolism (CVRN VTE) 
consortium. Our goal was to describe treatment strategies, morbidity, and mortality outcomes of both 
inpatients and outpatients with acute thromboembolism.  
 
Materials and Methods 
Cohort Assembly 
The CVRN VTE study is a retrospective cohort of patients with venous thromboembolism 
enrolled in one of four integrated healthcare delivery systems in the US. The four systems represented 
diverse geographic patient sources, with service provided during the study period to the following 
populations: Kaiser Permanente Northern California (>3.2 million members in Northern California 
during the study period), Kaiser Permanente Colorado (>460,000 members in the Denver, Colorado 
metropolitan area), Geisinger Health System, now Geisinger (~2.5 million members in central and 
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northwest Pennsylvania), and Marshfield Clinic (>550,000 members in central and northwest 
Wisconsin). All clinical sites used electronic health record systems during the time period of the study. 
The study was approved by the institutional review board at each of the participating sites according to 
local policies and procedures. A waiver of informed consent was obtained due to the nature of the study. 
The cohort was assembled by first searching computerized health plan databases for all 
individuals ≥21 years of age with a clinical encounter (inpatient, emergency department [ED] or 
ambulatory) associated with either a primary or secondary International Classification of Diseases, 
Ninth Revision (ICD-9) diagnosis code of venous thromboembolism, between October 1, 2004 and 
December 31, 2010. Only the first encounter with a code for venous thromboembolism during the time 
period was reviewed. Because the focus of the study was on incident thrombosis, patients with a prior 
code for thrombosis while enrolled in the health plan, or prescribed anticoagulants within 4 years prior, 
were excluded. We included only subjects with continuous health plan and pharmacy benefits for at least 
12 months prior to the index thrombotic encounter.  
Events were categorized as pulmonary embolism (ICD-9 code 415.1x), lower extremity deep 
venous thrombosis (451.1x, 451.2, 451.81, 453.4x, 453.5x), upper extremity deep venous thrombosis 
(451.83, 451.84, 451.89, 453.72, 453.73, 453.74, 453.75, 453.76, 453.77, 453.82, 453.83, 453.84, 
453.85, 453.86, 453.87), and other venous thrombosis (451, 451.9, 452, 453, 453.0, 453.1, 453.2, 453.3, 
453.79, 453.8, 453.89, 453.9). We did not include pregnancy-related thromboembolism or superficial 
thrombophlebitis as part of this study.  
 
Validation of Venous Thromboembolic Events 
We identified 42,941 unique individuals with an incident clinical encounter assigned a diagnosis 
of thromboembolism meeting inclusion criteria. To attain a target sample size of ~5500 patients with 
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valid, acute venous thrombosis, we initially selected 7,334 clinical encounters for review, comprising all 
available patients in two of the health systems and a random sample of patients from the other two 
systems. All available inpatient admission, transfer, discharge, ED, and outpatient encounter notes were 
redacted, as well as relevant radiology reports within 72 hours before and after the index venous 
thromboembolism date. Trained physician and pharmacist reviewers then reviewed medical records 
using a structured adjudication tool to determine whether the encounter represented a valid acute 
thromboembolism. Events were considered valid if there was radiographic, operative, or autopsy 
evidence of an acute thrombosis, or if a physician documented in the medical record that an acute 
venous thromboembolism had occurred during that episode of care. An encounter with a prior history of 
venous thromboembolism whose acute management was not contiguous with the current episode was 
not considered an acute event. Superficial venous thromboses/thrombophlebitis were not considered 
valid events.  
Of the initial 7,334 patients, 7,063 had medical records available for review. However, only 
2,135 (30.2%) were determined upon review to represent valid thromboembolism events, with 
ambulatory encounters and those with thrombosis codes in the secondary position less likely to represent 
true acute events (results of the validation process described previously).
8
 To enhance the likelihood of 
finding valid encounters, we then randomly selected an additional set of patients for review, restricting 
to hospital/ED encounters with a primary diagnosis of thrombosis in years 2006 or later, until we 
reached a total of ~5500 valid events (Supplemental Figure).   
 
Presentation, Treatment, and Outcomes of Acute Venous Thromboembolism 
Clinical and demographic information were obtained from computerized health plan databases. 
Relevant medical conditions within 4 years prior to the index event were identified using inpatient or 
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outpatient ICD-9 codes. Ascertainment of diabetes mellitus and malignant cancer was supplemented 
using regional diabetes and cancer registries from some of the health systems.
12, 13
 ICD-9 codes were 
used to calculate a Charlson comorbidity index score for each patient.
14
 Receipt of medications to 
manage chronic cardiovascular diseases were identified by searching health plan pharmacy dispensing 
databases within 30 days prior to the index thromboembolism date.  
Clinician reviewers collected information on thromboembolism type, smoking history, and 
documented immobility or injury (such as surgery within 30 days, trauma or prolonged immobility 
within 7 days, indwelling venous catheters). Thromboembolic events were defined as “unprovoked” if 
they occurred in the absence of identifiable risk factors such as diagnosed cancer or documented history 
of recent surgery, immobility, or injury. 
Reviewers assessed whether antithrombotic medications were prescribed at the end of the 
encounter and categorized as oral anticoagulants (specifically warfarin, as direct oral anticoagulants 
were not yet approved for use in thromboembolism), parenteral anticoagulants (e.g., low-molecular-
weight heparins, fondaparinux), and antiplatelet agents (aspirin, clopidogrel, ticlopidine, dipyridimole, 
and cilostazol). For encounters without antithrombotic treatment at discharge, the encounter 
documentation was reviewed for potential reasons why treatment was not issued. 
The primary outcome for the study was death from any cause within 90 days after the index 
thromboembolic event. Secondary outcomes included death during the index event, death within 30 
days, and new functional impairment at discharge. Death was determined from medical record review, 
health plan databases, and the Social Security Index death files. Functional impairment was ascertained 
by review of the encounter documentation. Reviewers used their clinical judgement to determine 
whether the patient suffered functional consequences as a result of the thrombotic event and categorized 
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as “at least some functional impairments related to the event”, “no functional impairments related to the 
event”, or “unknown”.  
 
Statistical Analysis 
 The study objective was to compare anticoagulant treatment patterns and short-term outcomes by 
thromboembolism type (any pulmonary embolism, lower extremity thrombosis, upper extremity 
thrombosis, and other venous thromboses). We first used descriptive statistics to report clinical 
characteristics, treatment, and outcomes by event type, using ANOVA for continuous variables and 
2
 
tests for categorical variables when comparing amongst thromboembolism types. We then modeled 
death within 90 days as a function of event type and anticoagulant treatment, developing a multivariable 
Cox regression model that incorporated variables that have been or could be plausibly be related to 
short-term mortality, including risk factors for thrombosis, coexisting medical conditions, Charlson 
comorbidity risk score, and baseline use of medications to manage cardiovascular conditions. A two-
sided p-value less than 0.05 was considered statistically significant. All analyses were performed using 
SAS version 9.1 (SAS Institute, Inc., Cary, NC).  
 
 
 Results 
The cohort comprised 5,497 adults with confirmed acute incident venous thromboembolism. The 
mean age of the cohort was 65.7 years and 51.4% were women (Table 1). The majority of subjects 
(n=3,056) had pulmonary embolism with or without concomitant deep venous thrombosis, followed by 
patients with isolated lower extremity thrombosis (n=1,928). Relatively few patients had isolated upper 
extremity thrombosis (n=383) or other forms of thrombosis (n=130).  
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Cancer was a common comorbid condition, present in 2,022 (36.4%) of patients overall and with 
a particularly high prevalence among people with upper extremity thrombosis (44.9%). Recent 
immobility and/or injury was identified in 2,302 (41.9%) of the cohort. In 188 (49.1%) of the 383 
patients with upper extremity thrombosis, an indwelling venous catheter was identified as a potential 
provoking event. For 1,254 (22.8%) of patients, the event was categorized as unprovoked (e.g., no 
history of immobility, injury, recent hospitalization, or known cancer).  
 
Treatment and outcomes of acute venous thromboembolism 
The majority of patients received anticoagulants (oral and/or parenteral) at discharge, although 
treatment differed by thrombosis type (Table 2). Among survivors of the acute event, 92.8% of those 
with pulmonary embolism and 86.9% of those with lower extremity thrombosis were discharged on 
anticoagulants. Anticoagulant treatment was less common among patients with thromboses in other 
locations: 80.1% of patients with upper extremity thrombosis and 54.8% of patients with other 
thrombosis. Few patients (2.9%) were discharged on antiplatelet agents only. Among the 430 patients 
who survived the acute episode and were not prescribed antithrombotic therapy at discharge, bleeding 
risk and/or poor prognosis were identified by reviewers as a rationale to avoid anticoagulants in 75.3% 
and 61.2% of patients, respectively. 
Death during the index thrombotic episode occurred in 5.2% of patients with pulmonary 
embolism and 3.1% of patients with lower extremity thrombosis (Table 2). Among patients who 
survived the index event, reviewers noted “at least some functional impairments related to the event” 
more commonly among patients with pulmonary embolism (26.1%) than patients with isolated lower 
extremity thrombosis (15.6%. p<0.01). The proportion of patients who died after the index event 
continued to rise after discharge: all-cause mortality was 8.0% at 30 days and 15.4% at 90 days (Table 
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2). Among all inpatients, 9.8% died within 30 days and 17.9% died within 90 days. In contrast, 2.5% 
and 7.7% of ED/ambulatory patients died within 30 and 90 days, respectively. Crude mortality at 90 
days was highest in patients with other thrombosis (25.4%), followed by isolated upper extremity 
thrombosis (20.9%) and then pulmonary embolism (15.5%). However, after multivariable adjustment, 
no significant differences in 90-day death rates persisted between these three groups (Table 3). In a 
multivariable Cox regression model, patients with pulmonary emboli had a higher 90-day mortality risk 
compared to patients with lower extremity thrombosis, with an adjusted hazard ratio [aHR] of 1.2 (95% 
confidence interval [CI] 1.04-1.5). Not being discharged on anticoagulants was associated with 
significantly higher mortality risk, aHR 5.6 (95% CI: 4.8-6.7). Other clinical factors associated with a 
higher risk of death at 90 days included older age, current smoking, a diagnosis of cancer, and higher 
Charlson comorbidity scores (Table 3).  
 
Discussion 
 Our study provides a unique examination of the acute presentation, treatment, and outcomes of 
inpatients and outpatients with venous thromboembolism across four geographically diverse US-based 
health systems. Although most patients with thromboembolism were treated with anticoagulants, 1 in 10 
people were not, frequently due to concerns for bleeding risk or poor clinical prognosis. The short-term 
outcomes after a diagnosis of thromboembolism are consequential, with 15.4% of patients dying within 
90 days after initial diagnosis.  
Strengths of our study include its diverse source population, inclusion of events from both 
inpatient and outpatient settings, and validation of index thromboembolic events and collection of data 
through review of medical records. These methods were then facilitated with additional data from 
comprehensive electronic medical records at each study site. We were able to identify health care 
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utilization even if patients presented to facilities outside of the healthcare system, as all patients were 
enrolled in integrated healthcare delivery systems. In contrast, most large, contemporary studies 
addressing acute venous thromboembolism in the US have relied on administrative data obtained from 
hospital settings, providing an incomplete perspective.
4, 5, 15, 16
 Our prior work found that only 30.9% of 
ambulatory encounters with a thrombosis diagnosis actually represented an acute thrombotic event .
8
 
With the advent of direct oral anticoagulants, it is likely that the outpatient treatment of 
thromboembolism will become even more prevalent. 
Descriptions of short-term outcomes following acute pulmonary embolism vary across different 
studies. The Multicenter Emergency Medicine Pulmonary Embolism in the Real World Registry 
(EMPEROR) study reported a relatively low 30-day mortality rate (5.4%) in patients with pulmonary 
embolism presenting to US-based emergency departments between 2005-2008
17
, comparable to the 
international Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) registry (5.9% 
mortality).
18
 In contrast, a Canadian study found a substantially higher (16.9%) 30-day mortality rate 
among hospitalized and ambulatory patients
19
 as did a Danish nationwide registry (19.9% 30-day 
mortality after hospitalization).
20
 The Nationwide Inpatient Sample, a nationally representative sample 
of US-hospital admissions, reported a declining risk of inpatient death after pulmonary embolism (7.1% 
in 1993 and 3.2% in 2012).
21
 Our study found that 5.2% of patients with pulmonary embolism died 
during the index event and 8.7% at 30 days. 
Variation in short-term outcomes observed across studies may have several possible 
explanations. One possibility may be differences in anticoagulation management and delivery; for 
example, the four health systems in our study were all integrated healthcare delivery models of care. Our 
study included patients treated in outpatient settings, who may have less severe disease and better 
functional status. Previous studies have shown that selective outpatient treatment of acute pulmonary 
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embolism is feasible and effective.
22-25
 Despite this, outpatient management of pulmonary embolism is 
still limited in clinical practice
18, 26-28
 Different follow-up periods could account for differences in case-
fatality rates, given secular trends of lower mortality from pulmonary embolism within the last two 
decades.
4, 18, 21
 Finally, the introduction and increased use of multidetector computed tomography may 
have contributed to including less severe or even clinically unimportant pulmonary emboli.
7, 29
   
In contrast to pulmonary embolism, we observed less discrepancy in 30-day mortality after deep 
venous thrombosis in our cohort compared to findings from the Worcester VTE study (5.4%),
30
 a 
Canadian study (7%),
19
 and a Danish registry (4.5%).
20
 Our results are consistent with other studies that 
show pulmonary embolism as an independent predictor of short-term death compared to deep venous 
thrombosis alone.
30-32
 
Most patients in our study were prescribed anticoagulants and anticoagulant treatment was 
associated with a significantly lower risk for 90-day death. Causality between treatment and mortality 
cannot be inferred, as it is highly likely there was channeling bias, where patients with limited life 
expectancy or at higher risk for adverse outcomes from anticoagulants were less likely to be prescribed 
treatment. Indeed, poor prognosis was commonly cited as a reason for avoiding therapy. Anticoagulation 
treatment varied by event type, with upper extremity thrombosis and thrombosis in unusual sites less 
likely to be treated with anticoagulants.  
Our results have several implications for practitioners, policy makers, and researchers. Our 
results underline the persistent public health importance of venous thromboembolism and highlight the 
substantial short-term mortality after incident thrombosis. Efforts to prevent thromboembolism and 
ensure timely diagnosis and treatment should be undertaken. Given that more than 19 billion dollars 
annually are spent for the treatment of thromboembolism in the US,
33
 with a substantial amount 
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accounting from in-hospital care,
34
 better education of clinicians about the appropriate risk stratification 
and the possibility of home treatment of patients could help to reduce costs.
26
  
There are also several limitations to this study. We oversampled for hospitalized patients, so 
preferentially captured more pulmonary embolism events and our findings might have been slightly 
biased towards patients with more severe disease. As a retrospective and observational study of clinical 
care, variation in documentation could have contributed to misclassification of certain variables, such as 
prior injury or immobility. Our study specifically addressed incident thrombosis and did not include 
recurrent thromboembolic events, which have different risk factors and outcomes. Finally, our study did 
not include the experience of patients with thrombosis who were treated with the direct oral 
anticoagulants, which were not yet in widespread use during the study period.
35
 Nevertheless, VKAs 
remain commonly prescribed in the US and worldwide.
36, 37
 
 
Conclusions 
 This large, multicenter cohort of patients with acute venous thromboembolism provides unique 
insights into treatment and outcomes of thromboembolism and demonstrated that anticoagulant 
treatment patterns and short-term mortality varied by event-type. Although case-fatality during the acute 
episode was relatively low, 15.4% of affected patients with acute thromboembolism died within 90 days 
of the incident event, highlighting the need for effective strategies to improve outcomes in this 
population. As treatment options continue to expand beyond warfarin to include direct oral 
anticoagulants, it is important to document how treatment and outcomes of thromboembolism evolves 
over time. 
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Supplementary Figure. Flow diagram of how 5,497 patients with valid, incident venous 
thromboembolism were identified for the CVRN VTE cohort 
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Table 1. Characteristics of 5,497 Patients with Acute Venous Thromboembolism 
 
 TOTAL Pulmonary 
embolism 
(with or 
without deep 
venous 
thrombosis) 
N=3056 
Lower 
extremity 
thrombosis 
N=1928 
Isolated 
upper 
extremity 
thrombosis 
N=383 
Isolated 
other 
thrombosis 
N=130 
P-
value17 
Age, mean years (SD) 65.7 (15.8) 65.7 (15.6) 66.5 (16.1) 62.8 (15.8) 61.1 (15.0) <0.001 
Women, n (%) 2824 (51.4) 1565 (51.2) 991 (51.4) 209 (54.6) 59 (45.4) 0.33 
Race, n (%)      <0.001 
White 4375 (79.6) 2437 (79.7) 1546 (80.2) 302 (78.9) 90 (69.2)  
Black 436 (7.9) 260 (8.5) 135 (7.0) 28 (7.3) 13 (10.0)  
Asian 
American/Pacific 
Islander 
161 (2.9) 85 (2.8) 46 (2.4) 19 (5.0) 11 (8.5)  
Other/unknown 525 (9.6) 274 (9.0) 201 (10.4) 34 (8.9) 16 (12.3)  
Hispanic ethnicity, n 
(%) 
391 (7.1) 200 (6.5) 138 (7.2) 40 (10.4) 13 (10.0) 0.02 
Treatment setting, n 
(%) 
     <0.001 
Hospital 4155 (75.6) 2902 (95.0) 878 (45.5) 267 (69.7) 108 (83.1)  
Emergency 
department or 
ambulatory clinic 
only 
1342 (24.4) 154 (5.0) 1050 (54.5) 116 (30.3) 22 (16.9)  
 
Baseline medical 
history, n (%) 
 
   
 
 
Hypertension 3165 (57.6) 1748 (57.2) 1118 (58.0) 225 (58.7) 74 (56.9) 0.91 
Diabetes mellitus 1178 (21.4) 624 (20.4) 416 (21.6) 108 (28.2) 30 (23.1) 0.006 
Cancer 2002 (36.4) 1115 (36.5) 665 (34.5) 172 (44.9) 50 (38.5) <0.001 
                                                 
17
 Comparison by thrombosis types 
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Prior ischemic 
stroke 
125 (2.3) 70 (2.3) 43 (2.2) 9 (2.3) 3 (2.3) 1.0 
Ischemic heart 
disease18 
558 (10.2) 312 (10.2) 208 (10.8) 35 (9.1) 3 (2.3) 0.02 
Heart failure 514 (9.4) 280 (9.2) 171 (8.9) 55 (14.4) 8 (6.2) 0.004 
Atrial fibrillation or 
flutter 
504 (9.2) 271 (8.9) 175 (9.1) 52 (13.6) 6 (4.6) 0.006 
Valvular heart 
disease 
320 (5.8) 162 (5.3) 120 (6.2) 32 (8.4) 6 (4.6) 0.07 
Chronic pulmonary 
disease19 
1065 (19.4) 623 (20.4) 325 (16.9) 104 (27.2) 13 (10.0) <0.001 
Chronic liver disease 181 (3.3) 75 (2.5) 63 (3.3) 19 (5.0) 24 (18.5) <0.001 
Hospitalization for 
sepsis 
195 (3.5) 90 (2.9) 74 (3.8) 29 (7.6) 2 (1.5) <0.001 
Inflammatory bowel 
disease 
98 (1.8) 50 (1.6) 35 (1.8) 9 (2.3) 4 (3.1) 0.51 
Hypercoagulable 
hematologic 
conditions20 
124 (2.3) 55 (1.8) 49 (2.5) 15 (3.9) 5 (3.8) 0.01 
Thrombophilia21 22 (0.4) 8 (0.3) 9 (0.5) 3 (0.8) 2 (1.5) 0.06 
Prior hospitalization 
for intracranial 
hemorrhage 
103 (1.9) 46 (1.5) 48 (2.5) 8 (2.1) 1 (0.8) 0.07 
Prior hospitalization 161 (2.9) 82 (2.7) 57 (3.0) 16 (4.2) 6 (4.6) 0.26 
                                                 
18
 Defined as acute myocardial infarction, unstable angina, percutaneous coronary intervention, or coronary artery bypass 
grafting 
19
 Defined as chronic obstructive pulmonary disease, emphysema, chronic bronchitis, chronic obstructive asthma, 
bronchiectasis, interstitial lung disease, pulmonary hypertension 
20
 Defined as polycythemia vera, paroxysmal nocturnal hemoglobinuria, homocystinuria, congenital deficiency of other 
clotting factors, defibrination syndrome, essential thrombocythemia, myelofibrosis with myeloid metaplasia, monoclonal 
paraproteinemia. 
21
 Defined as ICD-9 codes 289.81 (primary hypercoagulable state) and 289.82 (secondary hypercoagulable state) 
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for gastrointestinal 
hemorrhage 
Prior hospitalization 
for other 
hemorrhage 
41 (0.7) 19 (0.6) 19 (1.0) 2 (0.5) 1 (0.8) 0.50 
Prior hospitalization 
for mechanical fall 
32 (0.6) 17 (0.6) 14 (0.7) 1 (0.3) 0 (0.0) 0.54 
 
Baseline medication 
use, n (%) 
 
     
Angiotensin 
converting enzyme 
inhibitor 
1106 (20.1) 626 (20.5) 371 (19.2) 86 (22.5) 23 (17.7) 0.40 
Angiotensin II 
receptor blocker 
324 (5.9) 193 (6.3) 99 (5.1) 25 (6.5) 7 (5.4) 0.34 
Beta blocker 1730 (31.5) 978 (32.0) 603 (31.3) 118 (30.8) 31 (23.8) 0.26 
Calcium channel 
blocker 
807 (14.7) 470 (15.4) 262 (13.6) 59 (15.4) 16 (12.3) 0.29 
Diuretic 1615 (29.4) 924 (30.2) 540 (28.0) 112 (29.2) 39 (30.0) 0.41 
Aldosterone 
receptor antagonist 
152 (2.8) 81 (2.7) 42 (2.2) 18 (4.7) 11 (8.5) <0.001 
Alpha blocker 416 (7.6) 224 (7.3) 152 (7.9) 34 (8.9) 6 (4.6) 0.38 
Statin 1586 (28.9) 941 (30.8) 515 (26.7) 110 (28.7) 20 (15.4) <0.001 
Other lipid-lowering 
agent 
136 (2.5) 72 (2.4) 54 (2.8) 9 (2.3) 1 (0.8) 0.45 
Non-aspirin 
antiplatelet agent 
290 (5.3) 152 (5.0) 117 (6.1) 19 (5.0) 2 (1.5) 0.08 
Antidiabetic 
treatment 
736 (13.4) 411 (13.4) 240 (12.4) 66 (17.2) 19 (14.6) 0.09 
Non-steroidal anti-
inflammatory drugs 
588 (10.7) 353 (11.6) 192 (10.0) 34 (8.9) 9 (6.9) 0.08 
Current smoker, n (%) 438 (8.0) 228 (7.5) 147 (7.6) 43 (11.2) 20 (15.4) <0.001 
Hospitalization within 1045 (19.0) 580 (19.0) 349 (18.1) 94 (24.5) 22 (16.9) 0.03 
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30 days prior to index 
thrombotic event 
Recent 
immobility/injury, n 
(%) 
2302 (41.9) 1230 (40.2) 794 (41.2) 252 (65.8) 26 (20.0) <0.001 
Indwelling venous 
catheter 
301 (5.5) 76 (2.5) 32 (1.7) 188 (49.1)  5 (3.8)  
Prolonged 
immobility 
977 (17.8) 557 (18.2) 363 (18.8) 47 (12.3) 10 (7.7)  
Trauma/surgery 
within 30 days 
1172 (21.3) 621 (20.3) 446 (23.1) 94 (24.5) 11 (8.5)  
Charlson comorbidity 
index, n(%) 
     <0.001 
<1  1550 (28.2) 878 (28.7%) 568 (29.5) 64 (16.7) 40 (30.8)  
1-2 (mild) 1664 (30.3) 947 (31.0) 586 (30.5) 90 (23.5) 41 (31.5)  
3-4 (moderate) 910 (16.6) 505 (16.5) 317 (16.4) 72 (18.8) 16 (12.3)  
≥ 5 (severe)  1373 (25.0) 726 (23.8) 457 (23.7) 157 (41.0) 33 (25.4)  
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Table 2. Short-term Outcomes of 5,497 Adults with Acute Venous Thromboembolism 
 
 
 TOTAL 
N=5497 
Pulmonary 
embolism 
(with or 
without 
lower 
extremity 
thrombosis) 
N=3056 
Lower 
extremity 
thrombosis 
N=1928 
Isolated 
upper 
extremity 
thrombosis 
N=383 
Isolated 
other 
thrombosis 
N=130 
P-
value 
Disposition at discharge*      <0.05 
In-hospital death 
 
247 (4.5%) 158 (5.2%) 59 (3.1%) 26 (6.8%) 4 (3.1%)  
Alive, no functional 
impairment 
3746 
(68.1%) 
1953 (63.9%) 1422 (73.8%) 276 (72.1%) 95 (73.1%)  
Alive, with at least 
some functional 
impairment 
1185 
(21.6%) 
797 (26.1%) 301 (15.6%) 61 (15.9%) 26 (20.0%)  
Alive, unknown 
functional status 
319 (5.8%) 148 (4.8%) 146 (7.6%) 20 (5.2%) 5 (3.8%)  
       
Death within 30 days 439 (8.0%) 267 (8.7%) 112 (5.8%) 43 (11.2%) 18 (13.9%) <0.05 
       
Death within 90 days 846 
(15.4%) 475 (15.5%) 258 (13.4%) 80 (20.9%) 33 (25.4%) 
<0.05 
       
       
Antithrombotic 
treatment among 
survivors of acute 
N=5250 N=2898 N=1869 N=357 N=126 <0.05 
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thromboembolism 
Anticoagulant 
 
4668 
(88.9%) 
2688 (92.8%) 1625 (86.9%) 286 (80.1%) 69 (54.8%)  
Aspirin/other 
antiplatelet only 
 
152 (2.9%) 32 (1.1%) 94 (5.0%) 20 (5.6%) 6 (4.8%)  
*Functional impairment ascertained by review of encounter documentation. Reviewers asked to determine 
whether the patient suffered functional consequences as a result of the thrombotic event 
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Table 3. Significant predictors of death within 90 days in 5,497 adults with acute venous 
thromboembolism 
 Variable Adjusted Hazard Ratio* (95% CI) 
Venous thromboembolism type  
Pulmonary embolism ref 
Lower extremity thrombosis 0.81 (0.68-0.96) 
Upper extremity thrombosis 0.82 (0.64-1.05) 
Other thrombosis  0.85 (0.57-1.26) 
No anticoagulant treatment at discharge 5.6 [4.8-6.7] 
Age (years)   
< 60  ref 
60-69 1.49 (1.18-1.89) 
70-79 1.56 (1.24-1.97) 
≥ 80 2.39 (1.89-3.02) 
Current smoker 1.34 (1.03-1.75) 
Unprovoked thrombosis  0.70 (0.57-0.87) 
Treatment setting  
Inpatient ref 
Emergency department or outpatient 0.50 (0.40-0.62) 
Malignant cancer 1.38 (1.16-1.63) 
Charlson comorbidity index category  
<1 normal ref 
1-2 mild 1.42 (1.07-1.87) 
3-4 moderate 1.79 (1.32-2.41) 
≥ 5 severe 3.78 (2.81-5.09) 
*Multivariable models also adjusted for: gender, race, Hispanic ethnicity, hospitalization in the prior 30 days, 
specific medical conditions (unstable angina, acute myocardial infarction, stroke/transient ischemic attack, 
peripheral arterial disease,  chronic lung disease, chronic liver disease, diabetes mellitus, heart failure, dementia, 
inflammatory bowel disease, thrombophilia, sepsis, hypercoagulable hematologic conditions, intracranial 
hemorrhage, extracranial bleeding) and baseline medication use (ACE inhibitor, angiotensin receptor blocker, 
beta blocker, calcium channel blocker, diuretic, aldosterone receptor antagonist, alpha blockers, statin, non-
aspirin antiplatelet agent, diabetic therapy).  
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